Gsa Capital Partners LLP Avrobio, Inc. Transaction History

Gsa Capital Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.68 - $1.11 $104,004 - $169,772	-152,948 Reduced 46.31%	177,333 $114,000
Q2 2022 Aug 09, 2022	SELL	$0.75 - $1.33 $6,105 - $10,827	-8,141 Reduced 2.41%	330,281 $304,000
Q1 2022 May 11, 2022	BUY	$1.29 - $4.04 $155,167 - $485,951	120,285 Added 55.14%	338,422 $447,000
Q4 2021 Feb 14, 2022	BUY	$3.45 - $6.05 $101,323 - $177,682	29,369 Added 15.56%	218,137 $840,000
Q3 2021 Nov 12, 2021	BUY	$5.53 - $9.28 $660,182 - $1.11 Million	119,382 Added 172.05%	188,768 $1.05 Million
Q2 2021 Aug 05, 2021	BUY	$7.84 - $12.6 $264,529 - $425,136	33,741 Added 94.66%	69,386 $617,000
Q1 2021 May 10, 2021	BUY	$10.54 - $19.3 $151,660 - $277,707	14,389 Added 67.69%	35,645 $452,000
Q4 2020 Feb 03, 2021	BUY	$12.79 - $17.1 $271,864 - $363,477	21,256 New	21,256 $296,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.